Synapse - Solid Tumor Oncology Division

Results (22264)

Predictors of immediate and delayed cutaneous hypersensitivity reactions to paclitaxel

Journal Article

Trager, M. H.; Kuo, A. M.; Dusza, S. W.; Park, V.; Geskin, L.; Guyer, A.; Abuhadra, N.; Gucalp, A.; Lacouture, M. E.
Archives of Dermatological Research (2024)

Fulltext@MSK | Save

Safety and efficacy of BRAF inhibitor plixorafenib (FORE8394; PLX8394) in children and adults with recurrent, BRAF-altered primary central nervous system tumors (PCNST)

Meeting Abstract

de la Fuente, M.; Butowski, N. A.; Taylor, J.; Yaeger, R.; Tsai, F. Y. C.; Janku, F.; Allen, C. E.; Ammakkanavar, N.; Michelson, G.; Jiang, P.; more...
Neuro-Oncology (2024)

Fulltext@MSK | Save

Direct patient outreach in pediatric neurooncology to improve access to genomic profiling – The make-an-impact program

Meeting Abstract

Sait, S. F.; O'Donohue, T.; Hill, K.; Stockfish, E.; Giantini-Larsen, A.; Alano, T.; Bale, T.; Rosenblum, M.; Benhamida, J.; Dunkel, I.; more...
Neuro-Oncology (2024)

Fulltext@MSK | Save

Effects of aerobic training on determinants of peak oxygen consumption in post-treatment breast cancer

Meeting Abstract

Novo, R.; Michalski, M.; Stoeckel, K.; Lehman, S.; Yu, A.; Jones, L.; Eves, N.; Scott, J.
Medicine & Science in Sports & Exercise (2024)

Fulltext@MSK | Save

MAIN-CAV: Phase III randomized trial of maintenance cabozantinib (CABO) and avelumab (Av) vs Av after first-line platinum-based chemotherapy in patients (pts) with metastatic urothelial cancer (mUC; Alliance A032001)

Meeting Abstract

Gupta, S.; Ballman, K. V.; Apolo, A. B.; Sridhar, S. S.; Chen, R. C.; Wen, Y.; Yen, A. E.; Grivas, P.; Tan, A. L.; Baghaie, S.; more...
Journal of Clinical Oncology (2024)

Fulltext@MSK | Save

Phase 3 open-label, randomized, controlled study of disitamab vedotin with pembrolizumab versus chemotherapy in patients with previously untreated locally advanced or metastatic urothelial carcinoma that expresses HER2 (DV-001)

Meeting Abstract

Galsky, M. D.; Grande, E.; Necchi, A.; Koontz, M. Z.; Iyer, G.; Campbell, M. T.; Drakaki, A.; Loriot, Y.; Sokolowski, K. M.; Zhang, W.; more...
Journal of Clinical Oncology (2024)

Fulltext@MSK | Save

Prognostic utility of ctDNA detection in the monarchE trial of adjuvant abemaciclib plus endocrine therapy (ET) in HR+, HER2-, node-positive, high-risk early breast cancer (EBC)

Meeting Abstract

Loi, S.; Johnston, S. R. D.; Arteaga, C. L.; Graff, S. L.; Chandarlapaty, S.; Goetz, M. P.; Desmedt, C.; Sasano, H.; Liu, D.; Rodrik-Outmezguine, V.; more...
Journal of Clinical Oncology (2024)

Fulltext@MSK | Save

A phase 2 study of neoadjuvant PARP inhibition followed by radical prostatectomy (RP) in patients with unfavorable intermediate-risk or high-risk prostate cancer with BRCA1/2 gene alterations (NePtune)

Meeting Abstract

McKay, R. R.; Liu, L.; Pu, M.; Araneta, A.; Wang, L.; Castano, N.; Gomez, J.; Ajmera, A.; Ye, H.; Pili, R.; more...
Journal of Clinical Oncology (2024)

Fulltext@MSK | Save

P3BEP (ANZUP 1302): An international randomized phase 3 trial of accelerated versus standard BEP chemotherapy for individuals aged 11-45 years with intermediate and poor-risk metastatic germ cell tumours (GCTs)

Meeting Abstract

Mak, B.; Tran, B.; Pashankar, F. D.; Mazhar, D.; Huddart, R. A.; Wheater, M.; Walpole, E. T.; Feldman, D. R.; Dunwoodie, E.; Lawrence, N. J.; more...
Journal of Clinical Oncology (2024)

Fulltext@MSK | Save

PRECISION 1: A phase 2, multicenter, open-label basket trial of <i>nab</i>-sirolimus for malignant solid tumors harboring pathogenic inactivating alterations in TSC1 and TSC2

Meeting Abstract

Iyer, G.; Kwiatkowski, D. J.; Ding, L.; Schmid, A. N.; Navarro, W. H.; Ahnert, J. R.
Journal of Clinical Oncology (2024)

Fulltext@MSK | Save